1 week Ago By ABMN Staff
Fennec Pharmaceuticals Inc. ( TSE:FRX – Get Free Report ) shares hit a new 52-week low during trading on Friday . The company traded as low as C$7.
00 and last traded at C$7.00, with a volume of 101 shares trading hands. The stock had previously closed at C$7.
24. Fennec Pharmaceuticals Price Performance The company has a market capitalization of C$195.35 million, a price-to-earnings ratio of 79.
33 and a beta of 0.26. The business has a fifty day moving average price of C$8.
17 and a 200 day moving average price of C$10.59. The company has a debt-to-equity ratio of 1,040.
68, a current ratio of 8.02 and a quick ratio of 10.17.
Fennec Pharmaceuticals ( TSE:FRX – Get Free Report ) last issued its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of C$0.
08 by C($0.35). Fennec Pharmaceuticals had a negative return on equity of 1,005.
59% and a net margin of 5.59%. The company had revenue of C$9.
94 million during the quarter, compared to analyst estimates of C$18.67 million. On average, research analysts expect that Fennec Pharmaceuticals Inc.
will post 0.6058577 earnings per share for the current fiscal year. Fennec Pharmaceuticals Company Profile Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States.
The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Read More Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
